STOCK TITAN

Sight Sciences to Present at the Upcoming Citi 2023 Healthcare Services, Medtech, Tools & HCIT Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology firm, announced its participation in the Citi 2023 Healthcare Services, Medtech, Tools & HCIT Conference in New York on March 1, 2023, at 3:30 PM ET. The company will host a fireside chat, which will be accessible live and archived on its website’s 'Investors' section. Sight Sciences focuses on innovative, minimally invasive solutions for prevalent eye diseases, including the OMNI® Surgical System for glaucoma and the TearCare® System for dry eye disease. These advancements aim to enhance patient care and replace outdated treatment methods.

Positive
  • None.
Negative
  • None.

MENLO PARK, Calif., Feb. 22, 2023 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform care and improve patients’ lives, today announced plans to present at the upcoming Citi 2023 Healthcare Services, Medtech, Tools & HCIT Conference in New York, NY.

Sight Sciences’ management is scheduled to participate in a fireside chat on Wednesday, March 1, 2023, at 3:30pm ET. Interested parties may access a live and archived webcast of the fireside chat on the “Investors” section of the company’s website at: https://investors.sightsciences.com/.

About Sight Sciences
Sight Sciences is an eyecare technology company focused on developing and commercializing innovative solutions intended to transform care and improve patients’ lives. Using minimally invasive or non-invasive approaches to target the underlying causes of the world’s most prevalent eye diseases, Sight Sciences seeks to create more effective treatment paradigms that enhance patient care and supplant conventional outdated approaches. The Company’s OMNI® Surgical System is a minimally invasive glaucoma surgery (MIGS) device indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma (POAG), the world’s leading cause of irreversible blindness. The Company’s TearCare® System is 510(k) cleared for the application of localized heat therapy in adult patients with evaporative dry eye disease due to meibomian gland dysfunction (MGD), enabling office-based clearance of gland obstructions by physicians to address the leading cause of dry eye disease. The Company’s SION™ Surgical Instrument is a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork.

For more information, visit www.sightsciences.com.

OMNI® and TearCare® are registered trademarks of Sight Sciences.
SION™ is a trademark of Sight Sciences.
© 2023 Sight Sciences. All rights reserved.

Investor contact:
Philip Taylor
Gilmartin Group
415.937.5406
Investor.Relations@Sightsciences.com


FAQ

What is the date of Sight Sciences' presentation at the Citi 2023 Healthcare Conference?

Sight Sciences will present on March 1, 2023.

What time is the fireside chat for Sight Sciences at the conference?

The fireside chat is scheduled for 3:30 PM ET.

How can I access the webcast of the Sight Sciences fireside chat?

The webcast can be accessed live and archived on the 'Investors' section of the Sight Sciences website.

What technologies does Sight Sciences focus on?

Sight Sciences develops minimally invasive solutions for glaucoma and dry eye disease.

What is the purpose of the OMNI® Surgical System?

The OMNI® Surgical System is designed to reduce intraocular pressure in patients with glaucoma.

What condition does the TearCare® System address?

The TearCare® System targets evaporative dry eye disease due to meibomian gland dysfunction.

Sight Sciences, Inc.

NASDAQ:SGHT

SGHT Rankings

SGHT Latest News

SGHT Stock Data

230.41M
50.31M
20.08%
50.9%
2.22%
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States of America
MENLO PARK